A focus on cocaine and crack addiction;Le point sur l'addiction à la cocaïne et au crack

Annales Medico-Psychologiques

Volumn 167, Issue 7, 2009, Pages 504-507

  Charles Nicolas, A ^a   Lacoste, J ^a   Ballon, N ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

Author keywords

Cocaine; Crack; French West Indies

Indexed keywords

ARIPIPRAZOLE; BACLOFEN; COCAINE; GABAPENTIN; MODAFINIL; OLANZAPINE; PLACEBO; RIMONABANT; RISPERIDONE; TIAGABINE; TOPIRAMATE; VACCINE; VIGABATRIN;

AGE DISTRIBUTION; AGITATION; ANXIETY; ARTICLE; COCAINE DEPENDENCE; DYSPHORIA; EUPHORIA; FATIGUE; HALLUCINATION; HISTORY; HUMAN; HYPERPNEA; HYPERTENSION; HYPERTHERMIA; INSOMNIA; INTOXICATION; IRRITABILITY; MYDRIASIS; TACHYCARDIA; WESTERN EUROPE; WITHDRAWAL SYNDROME;

EID: 69749101482     PISSN: 00034487     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amp.2009.06.016     Document Type: Article

References (30)

1. Albertson T.E., Walby W.F., and Derlet R.W. Stimulant-induced pulmonary toxicity. Chest 108 (1995) 1140-1149
2. Ballon N, Lacoste J, Charles-Nicolas A. Cocaïne et crack. In: Reynaud M, Traité d'addictologie. Paris;2006.
3. Ballon N., Leroy S., Roy C., Bourdel M.C., Charles-Nicolas A., Krebs M.O., et al. (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. Pharmacogenomics J 6 (2006) 126-130
4. Ballon N., Leroy S., Roy C., Bourdel M.C., Olie J.P., Charles-Nicolas A., et al. Polymorphisms TaqI A of the DRD2, BalI of the DRD3, exon III repeat of the DRD4, and 3' UTR VNTR of the DAT: Association with childhood ADHD in male African-Caribbean cocaine dependents?. Am J Med Genet B Neuropsychiatr Genet 144 (2007) 1034-1041
5. Blaho K., Logan B., Winbery S., Park L., and Schwilke E. Blood cocaine and metabolite concentrations, clinical findings, and outcome of patients presenting to an ED. Am J Emerg Med 18 (2000) 593-598
6. Brown E.S., Jeffress J., Liggin J.D., Garza M., and Beard L. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry 66 (2005) 756-760
7. Charles-Nicolas A. Toxicomanies. In: Hamburger J., and Godeau P. (Eds). Traité de Médecine 2 (1981), Flammarion, Paris
8. Charles-Nicolas A. Crack et Cannabis dans la Caraïbe. Paris, 1998.
9. Clemessy J.L., and Baud F.J. Intoxication aiguë par les opiacés, la cocaine et l'ecstasy. Concours Med 120 (1998) 24-27
10. Dackis C.A., Kampman K.M., Lynch K.G., Pettinati H.M., and O'Brien C.P. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30 (2005) 205-211
11. Dackis C.A., Lynch K.G., Yu E., Samaha F.F., Kampman K.M., Cornish J.W., et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 70 (2003) 29-37
12. De Vries T.J., Shaham Y., Homberg J.R., Crombag H., Schuurman K., Dieben J., et al. A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 7 (2001) 1151-1154
13. Deroche-Gamonet V., Sillaber I., Aouizerate B., Izawa R., Jaber M., Ghozland S., et al. The glucocorticoid receptor as a potential target to reduce cocaine abuse. J Neurosci 23 (2003) 4785-4790
14. Haim D.Y., Lippmann M.L., Goldberg S.K., and Walkenstein M.D. The pulmonary complications of crack cocaine. A comprehensive review. Chest 107 (1995) 233-240
15. Hart C.L., Ward A.S., Collins E.D., Haney M., and Foltin R.W. Gabapentin maintenance decreases smoked cocaine-related subjective effects, but not self-administration by humans. Drug Alcohol Depend 73 (2004) 279-287
16. Hrafnkelsdottir K., Valgeirsson J., and Gizurarson S. Induction of protective and specific antibodies against cocaine by intranasal immunisation using a glyceride adjuvant. Biol Pharm Bull 28 (2005) 1038-1042
17. Kampman K.M., Pettinati H., Lynch K.G., Dackis C., Sparkman T., Weigley C., et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 75 (2004) 233-240
18. Kantak K.M. Anti-cocaine vaccines: antibody protection against relapse. Expert Opin Pharmacother 4 (2003) 213-218
19. Karch S.B. The history of cocaine toxicity. Hum Pathol 20 (1989) 1037-1039
20. Karch S.B. Interpretation of blood cocaine and metabolite concentrations. Am J Emerg Med 18 (2000) 635-636
21. Lile J.A., Stoops W.W., Glaser P.E.A., Hays L.R., and Rush C.R. Acute administration of the GABA reuptake inhibitor tiagabine does not alter the effects of oral cocaine in humans. Drug Alcohol Depend 76 (2004) 81-91
22. Martell B.A., Mitchell E., Poling J., Gonsai K., and Kosten T.R. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 58 (2005) 158-164
23. Merle S. Estimation locale de l'usage problématique de drogues : l'enquête NEMO. OSM-Flash (2007) 40
24. Mets B., Winger G., Cabrera C., Seo S., Jamdar S., Yang G., et al. A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats. Proc Natl Acad Sci U S A 95 (1998) 10176-10181
25. Myrick H., Henderson S., Brady K.T., and Malcolm R. Gabapentin in the treatment of cocaine dependence: a case series. J Clin Psychiatry 62 (2001) 19-23
26. OEDT. État du phénomène de la drogue en Europe. http://www.ofdt.fr/BDD/publications/docs/NR07rapp.pdf, 59.2007.
27. OFDT. Drogues et dépendances. Indicateurs et tendances. Paris;2002.
28. Piomelli D. Cannabinoid activity curtails cocaine craving. Nat Med 7 (2001) 1099-1100
29. Salomon L., Lanteri C., Glowinski J., and Tassin J.P. Behavioral sensitization to amphetamine results from an uncoupling between noradrenergic and serotonergic neurons. Proc Natl Acad Sci USA 103 (2006) 7476-7481
30. Thadani P.V. NIDA conference report on cardiopulmonary complications of "crack" cocaine use. Clinical manifestations and pathophysiology. Chest 110 (1996) 1072-1076